Targeted Protein Degradation in Oncology Market Report: 2027-2031 Forecast, Strategic Opportunities by Modality, Indication, Target, E3 Ligase, Product and Country - Strategic Analysis of 12 Companies

1.1 Situation Analysis
1.2 Market Snapshot
1.3 Key Findings
1.4 Investment & Strategic Thesis

2.1 Forecast Approach
2.2 Data Sources
2.3 Scope & Definitions
2.4 Limitations

3.1 Mechanism of Action & Key Components
3.2 Evolution of the Technology
3.3 Adjacent Modalities

4.1 Global Market Overview by Country
4.2 Global Market by Modality - Overview
4.3 Global Market by Indication - Overview
4.4 Global Market by Target - Overview
4.5 Global Market by E3 Ligase - Overview
4.6 Global Market by Product - Overview

5.1 Approved Product Registry
5.2 Technology Benchmarking
5.3 Commercial Benchmarking - Top-Selling Products
5.4 Regulatory Risk Case Studies

6.1 Pipeline Overview
6.2 Pipeline Distribution by Phase
6.3 Target & Indication Crowding
6.4 Sponsor Geographic Distribution

7.1 Core Platform Technologies
7.2 Next-Generation Approaches
7.3 Delivery & Formulation
7.4 Platform Technology Licensors

8.1 Combinations with Immunotherapy
8.2 Combinations with Targeted Therapy
8.3 Commercial and Biological Rationale

9.1 FDA Approval Pathways
9.2 EMA & NMPA Pathways
9.3 HTA & Reimbursement Dynamics
9.4 Patent & Biosimilar Overview

10.1 Expiry Timeline
10.2 Biosimilar & Generic Pipeline
10.3 Anticipated Price Erosion

11.1 Key Originators
11.2 Why Global Pharma Is Buying In

12.1 Recent Developments - Importance and How to Use This Section
12.2 Johnson & Johnson acquires Halda Therapeutics for $3.05 billion
12.3 First U.S. generic pomalidomide launches
12.4 BMS's mezigdomide succeeds in Phase 3
12.5 Roche partners with C4 Therapeutics on degrader-antibody conjugates
12.6 FDA approves Veppanu, the first PROTAC
12.7 Roche to co-develop Nurix's BTK degrader
12.8 Rigel licenses Veppanu from Arvinas and Pfizer
12.9 FDA approves Zenbexus, the first CELMoD
12.10 BeOne reports strong BTK degrader data at EHA
12.11 Roche signs molecular glue deal with Hangzhou Defand

13.1 Manufacturing Capacity Landscape
13.2 CDMO Competitive Positioning
13.3 In-House vs. Outsourced Manufacturing Trends
13.4 Capacity Bottlenecks and Outlook

14.1 Market Structure
14.2 Big Pharma / Large-Cap Portfolios
14.3 Emerging and China-Originated Players
14.4 Outlook

15.1 SWOT Analysis
15.2 Porter's Five Forces
15.3 Key Investment Risks

16.1 White-Space Opportunities
16.2 Partnering Strategy Guidance

17.1 IMiDs (lenalidomide, pomalidomide)
17.2 CELMoDs
17.3 PROTACs
17.4 Degrader-antibody conjugates
17.5 Other modalities

18.1 Multiple myeloma
18.2 Breast cancer
18.3 Prostate cancer
18.4 Lymphoma & leukemia
18.5 Other solid tumors
18.6 Other indications

19.1 IKZF1/3 (cereblon neosubstrates)
19.2 Estrogen receptor
19.3 Androgen receptor
19.4 BTK
19.5 Other targets

20.1 Cereblon (CRBN)
20.2 VHL
20.3 Other / novel ligases

21.1 Revlimid & generic lenalidomide
21.2 Pomalyst & generic pomalidomide
21.3 Vepdegestrant
21.4 Iberdomide
21.5 Mezigdomide
21.6 BGB-16673 (BTK degrader)
21.7 Bexobrutideg (BTK degrader)
21.8 BMS-986365 (AR degrader)
21.9 Other products

22.1 Arvinas
22.2 Bristol Myers Squibb
22.3 C4 Therapeutics
22.4 Halda Therapeutics
22.5 Johnson & Johnson
22.6 Monte Rosa Therapeutics
22.7 NATCO Pharma
22.8 Novartis
22.9 Nurix Therapeutics
22.10 Pfizer
22.11 Rigel Pharmaceuticals
22.12 Roche

23.1 Abbreviations
23.2 Report Limitations Restated

Table 1 Global Market by Country
Table 2 Global Market by Modality
Table 3 Global Market by Indication
Table 4 Global Market by Target
Table 5 Global Market by E3 Ligase
Table 6 Global Market by Product
Table 7 IMiDs (lenalidomide, pomalidomide) by Country
Table 8 CELMoDs by Country
Table 9 PROTACs by Country
Table 10 Degrader-antibody conjugates by Country
Table 11 Other modalities by Country
Table 12 Multiple myeloma by Country
Table 13 Breast cancer by Country
Table 14 Prostate cancer by Country
Table 15 Lymphoma & leukemia by Country
Table 16 Other solid tumors by Country
Table 17 Other indications by Country
Table 18 IKZF1/3 (cereblon neosubstrates) by Country
Table 19 Estrogen receptor by Country
Table 20 Androgen receptor by Country
Table 21 BTK by Country
Table 22 Other targets by Country
Table 23 Cereblon (CRBN) by Country
Table 24 VHL by Country
Table 25 Other / novel ligases by Country
Table 26 Revlimid & generic lenalidomide by Country
Table 27 Pomalyst & generic pomalidomide by Country
Table 28 Vepdegestrant by Country
Table 29 Iberdomide by Country
Table 30 Mezigdomide by Country
Table 31 BGB-16673 (BTK degrader) by Country
Table 32 Bexobrutideg (BTK degrader) by Country
Table 33 BMS-986365 (AR degrader) by Country
Table 34 Other products by Country

Figure 1 Key Graphic - The degrader market turns over
Figure 2 Global Market Pareto Chart
Figure 3 Global Market by Modality - Base vs. Final
Figure 4 Global Market by Modality Base Year
Figure 5 Global Market by Modality End Year
Figure 6 Modality Share by Year
Figure 7 Modality Segments Growth
Figure 8 Global Market by Indication - Base vs. Final
Figure 9 Global Market by Indication Base Year
Figure 10 Global Market by Indication End Year
Figure 11 Indication Share by Year
Figure 12 Indication Segments Growth
Figure 13 Global Market by Target - Base vs. Final
Figure 14 Global Market by Target Base Year
Figure 15 Global Market by Target End Year
Figure 16 Target Share by Year
Figure 17 Target Segments Growth
Figure 18 Global Market by E3 Ligase - Base vs. Final
Figure 19 Global Market by E3 Ligase Base Year
Figure 20 Global Market by E3 Ligase End Year
Figure 21 E3 Ligase Share by Year
Figure 22 E3 Ligase Segments Growth
Figure 23 Global Market by Product - Base vs. Final
Figure 24 Global Market by Product Base Year
Figure 25 Global Market by Product End Year
Figure 26 Product Share by Year
Figure 27 Product Segments Growth
Figure 28 IMiDs (lenalidomide, pomalidomide) Growth
Figure 29 CELMoDs Growth
Figure 30 PROTACs Growth
Figure 31 Degrader-antibody conjugates Growth
Figure 32 Other modalities Growth
Figure 33 Multiple myeloma Growth
Figure 34 Breast cancer Growth
Figure 35 Prostate cancer Growth
Figure 36 Lymphoma & leukemia Growth
Figure 37 Other solid tumors Growth
Figure 38 Other indications Growth
Figure 39 IKZF1/3 (cereblon neosubstrates) Growth
Figure 40 Estrogen receptor Growth
Figure 41 Androgen receptor Growth
Figure 42 BTK Growth
Figure 43 Other targets Growth
Figure 44 Cereblon (CRBN) Growth
Figure 45 VHL Growth
Figure 46 Other / novel ligases Growth
Figure 47 Revlimid & generic lenalidomide Growth
Figure 48 Pomalyst & generic pomalidomide Growth
Figure 49 Vepdegestrant Growth
Figure 50 Iberdomide Growth
Figure 51 Mezigdomide Growth
Figure 52 BGB-16673 (BTK degrader) Growth
Figure 53 Bexobrutideg (BTK degrader) Growth
Figure 54 BMS-986365 (AR degrader) Growth
Figure 55 Other products Growth